IL4R and nasal cavity polyp: Dupilumab, an anti-IL-4 receptor alpha (IL-4Rα) monoclonal antibody (mAb), targets IL-4 and IL-13 signaling simultaneously, and its administration has been demonstrated to significantly improve a patient’s nasal polyp score (NPS), nasal congestion or obstruction, and sinus Lund-Mackay (LM) CT scores in two phase-III big trials [80].